ABOUT INDEXING BOARD ARCHIVES AUTHOR GUIDELINES SUBMIT PAPER AUTHORS'S PAGE NEWS, EVENTS
REVISTA DE CHIMIE
Cite as: Rev. Chim.
https://doi.org/10.37358/Rev.Chim.1949

OSIM Nr. R102355
ISSN Print 0034-7752
ISSN Online 2668-8212
Journal Metrics
* Impact Factor 2018-19: 1.605
* 5-Year IF: 1.34
* CiteScore: 1.23
* SNIP: 0.710
* SJR: 0.294
(academic-accelerator.com)

REVISTA DE CHIMIE Latest Issue

LATEST ISSUE >>>

   Volume 71, 2020
   Volume 70, 2019
   Volume 69, 2018
   Volume 68, 2017
   Volume 67, 2016
   Volume 66, 2015
   Volume 65, 2014
   Volume 64, 2013
   Volume 63, 2012
   Volume 62, 2011
   Volume 61, 2010
   Volume 60, 2009
   Volume 59, 2008
   Volume 58, 2007
   Volume 57, 2006
   Volume 56, 2005
   Volume 55, 2004
   Volume 54, 2003
   Volume 53, 2002
 
<<<< back

Revista de Chimie (Rev. Chim.), Year 2019, Volume 70, Issue 12, 4499-4503

https://doi.org/10.37358/RC.19.12.7783

Ema Borsi, Adina Bucur, Ioana Ionita, Cristina Potre-Oncu, Ovidiu Potre-Oncu, Raluca Tudor, Emanuela Georgiana Gal-Nadasal, Hortensia Ionita

Advantages and Drawbacks of Carfilzomib vs. Bortezomib

Abstract:

In myeloma therapy, various biological parameters are considered to have an effect on disease evolution and guiding the course of treatment. In the present study we have enrolled 105 patients with Multiple Myeloma admitted in the Hematology Department within the City Emergency Clinical Hospital Timisoara over a 4-year period. This study aims to assess the adverse events, response and overall survival after administration of bortezomib and dexamethasone vs. carfilzomib and dexamethasone regimens.
Keywords:
Carfilzomib; Bortezomib; Multiple myeloma

Issue: 2019, Volume 70, Issue 12
Pages: 4499-4503
Publication date: 20/01/2020
https://doi.org/10.37358/RC.19.12.7783
download pdf   Download Pdf Article
Creative Commons License
This article is published under the Creative Commons Attribution 4.0 International License
Citation Styles
Cite this article as:
BORSI, E., BUCUR, A., IONITA, I., POTRE-ONCU, C., POTRE-ONCU, O., TUDOR, R., GAL-NADASAL, E.G., IONITA, H., Advantages and Drawbacks of Carfilzomib vs. Bortezomib, Rev. Chim., 70(12), 2019, 4499-4503.

Vancouver
Borsi E, Bucur A, Ionita I, Potre-Oncu C, Potre-Oncu O, Tudor R, Gal-Nadasal EG, Ionita H. Advantages and Drawbacks of Carfilzomib vs. Bortezomib. Rev. Chim.[internet]. 2019 Dec;70(12):4499-4503. Available from: https://doi.org/10.37358/RC.19.12.7783


APA 6th edition
Borsi, E., Bucur, A., Ionita, I., Potre-Oncu, C., Potre-Oncu, O., Tudor, R., Gal-Nadasal, E.G. & Ionita, H. (2019). Advantages and Drawbacks of Carfilzomib vs. Bortezomib. Revista de Chimie, 70(12), 4499-4503. https://doi.org/10.37358/RC.19.12.7783


Harvard
Borsi, E., Bucur, A., Ionita, I., Potre-Oncu, C., Potre-Oncu, O., Tudor, R., Gal-Nadasal, E.G., Ionita, H. (2019). 'Advantages and Drawbacks of Carfilzomib vs. Bortezomib', Revista de Chimie, 70(12), pp. 4499-4503. https://doi.org/10.37358/RC.19.12.7783


IEEE
E. Borsi, A. Bucur, I. Ionita, C. Potre-Oncu, O. Potre-Oncu, R. Tudor, E.G. Gal-Nadasal, H. Ionita, "Advantages and Drawbacks of Carfilzomib vs. Bortezomib". Revista de Chimie, vol. 70, no. 12, pp. 4499-4503, 2019. [online]. https://doi.org/10.37358/RC.19.12.7783


Text
Ema Borsi, Adina Bucur, Ioana Ionita, Cristina Potre-Oncu, Ovidiu Potre-Oncu, Raluca Tudor, Emanuela Georgiana Gal-Nadasal, Hortensia Ionita,
Advantages and Drawbacks of Carfilzomib vs. Bortezomib,
Revista de Chimie,
Volume 70, Issue 12,
2019,
Pages 4499-4503,
ISSN 2668-8212,
https://doi.org/10.37358/RC.19.12.7783.
(https://revistadechimie.ro/Articles.asp?ID=7783)
Keywords: Carfilzomib; Bortezomib; Multiple myeloma


RIS
TY - JOUR
T1 - Advantages and Drawbacks of Carfilzomib vs. Bortezomib
A1 - Borsi, Ema
A2 - Bucur, Adina
A3 - Ionita, Ioana
A4 - Potre-Oncu, Cristina
A5 - Potre-Oncu, Ovidiu
A6 - Tudor, Raluca
A7 - Gal-Nadasal, Emanuela Georgiana
A8 - Ionita, Hortensia
JF - Revista de Chimie
JO - Rev. Chim.
PB - Revista de Chimie SRL
SN - 2668-8212
Y1 - 2019
VL - 70
IS - 12
SP - 4499
EP - 4503
UR - https://doi.org/10.37358/RC.19.12.7783
KW - Carfilzomib
KW - Bortezomib
KW - Multiple myeloma
ER -


BibTex
@article{RevCh2019P4499,
author = {Borsi Ema and Bucur Adina and Ionita Ioana and Potre-Oncu Cristina and Potre-Oncu Ovidiu and Tudor Raluca and Gal-Nadasal Emanuela Georgiana and Ionita Hortensia},
title = {Advantages and Drawbacks of Carfilzomib vs. Bortezomib},
journal = {Revista de Chimie},
volume = {70},
number = {12},
pages = {4499-4503},
year = {2019},
issn = {2668-8212},
doi = {https://doi.org/10.37358/RC.19.12.7783},
url = {https://revistadechimie.ro/Articles.asp?ID=7783}
}
 
Views number: 66    |     Downloads number: 0  
<<<< back
 
PUBLISHING SECTION
Author Guidelines
 * Paper Drafting
 * Paper Template
 * Ethical Statement
 * Paper Submission
 * Author Payments
Ghidul Autorului (ro)
Submit Paper
Author's Page
Publishing Ethics
Open Access Policy
 Search Authors
 LATEST NEWS
REvista de Chimie Revista de Chimie - 70 de ani de aparitie neintrerupta.. detalii
dictionar English-Romanian Dictionary for Mechanical Engineering
(download pdf)
  News, Events
Crossref Member Badge
 DOI  logo
 Gold Open Access | Source=http://www.plos.org/  | Author=art designer at PLoS
Creative Commons License
 Conferences of Contemporary
 Chemistry
 Biblioteca Chimiei
 Materiale Plastice